Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy

Trius Therapeutics Announces Publication of Antibiotic Safety Study in
Antimicrobial Agents and Chemotherapy

Peer-Reviewed Results Suggest No Clinically Significant Interactions Between
Trius' Experimental Antibiotic Tedizolid and a Commonly Used Class of
Medications

SAN DIEGO, June 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX), a biopharmaceutical company focused on the discovery,
development and commercialization of antibiotics for serious infections, today
announced the publication of the results of multiple clinical and animal
studies showing the company's experimental antibiotic, tedizolid phosphate
(TR-701), does not interact with monamine oxidase (MAO). MAO is an enzyme
involved in the regulation of neurotransmitters such as serotonin,
norepinephrine and dopamine, and its inhibition can lead to serious drug-drug
interactions. These results were published in the July 2013 (Volume 57 Number
7) print issue of Antimicrobial Agents and Chemotherapy.

The findings suggest tedizolid, if approved, could potentially be taken with
commonly prescribed medicines such as many antidepressants, whose use is
limited with agents that inhibit MAO. Some other antibiotics are associated
with rare but significant neurological adverse events when used with such
agents. For example, linezolid (Zyvox®) exhibits drug interactions when taken
with medicines that lead to increased serotonin levels, such as selective
serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake
inhibitors (SNRIs). This may cause serotonin syndrome, which is a
life-threatening neurological condition. Other adverse drug reactions that may
result from interactions with MAO inhibitors include hypertensive (high blood
pressure) crisis caused by combination with vasoconstrictors (blood pressure
medications), and hypoglycemia (low blood sugar) caused by combination with
insulin or anti-diabetic medicines.

"We are encouraged that tedizolid dosed at up to 25 times above its human
therapeutic use did not appear to alter MAO function in these studies," said
Philippe Prokocimer, Chief Medical Officer at Trius Therapeutics. "The studies
suggest that, unlike linezolid, tedizolid could be taken without restriction
by patients on many common antidepressants and other medicines that inhibit
MAO, subject to agreement by regulatory authorities."

Trius will include these results in its new drug application (NDA) for
tedizolid for the treatment of acute bacterial skin and skin structure
infections (ABSSSI). The company plans to submit the NDA to the Food & Drug
Administration (FDA) in the second half of 2013.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the Company's planned
NDA filing for tedizolid and the FDA's agreement with Trius' conclusions
regarding its studies relating to the interaction of tedizolid and MAO. Risks
that contribute to the uncertain nature of the forward-looking statements
include: the accuracy of Trius' estimates regarding expenses, future revenues
and capital requirements; the success and timing of Trius' preclinical studies
and clinical trials; regulatory developments in the United States and foreign
countries; changes in Trius' plans to develop and commercialize its product
candidates; any negative or inconclusive results of additional ongoing or
planned clinical trials of tedizolid phosphate; additional clinical trials or
the modification Trius' ongoing clinical trials decided upon by Trius or
required by the FDA; delays in the commencement, enrollment, completion or
analysis of clinical testing for Trius' product candidates, or significant
issues regarding the adequacy of its clinical trial designs or the execution
of its clinical trials, which could result in increased costs and delays, or
limit Trius' ability to obtain regulatory approval; any failure of expected
performance by the third parties with whom Trius has partnered with for the
development of tedizolid phosphate and upon whom Trius relies to conduct its
clinical trials and manufacture its product candidates; the failure of
tedizolid phosphate to receive regulatory approval or to be successfully
commercialized; unexpected adverse side effects or inadequate therapeutic
efficacy of tedizolid phosphate that could delay or prevent regulatory
approval or commercialization; Trius' ability to obtain and maintain
intellectual property protection for its product candidates; and the loss of
key scientific or management personnel. These and other risks and
uncertainties are described more fully in Trius' most recent Form 10-K, Forms
10-Q and other documents filed with the United States Securities and Exchange
Commission, including those factors discussed under the caption "Risk Factors"
in such filings. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Trius undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
 
Press spacebar to pause and continue. Press esc to stop.